Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1994 1
1997 1
2001 1
2002 1
2003 3
2004 2
2005 3
2006 1
2007 5
2008 8
2009 6
2010 5
2011 5
2012 4
2013 5
2014 8
2015 9
2016 13
2017 20
2018 16
2019 15
2020 11
2021 9
2022 7
2023 10
2024 13
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. Among authors: lindstrom v. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B. Fürstenau M, et al. Among authors: lindstrom v. Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7. Lancet Oncol. 2024. PMID: 38821083 Free article. Clinical Trial.
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Al-Sawaf O, Fürstenau M, Giza A, Robrecht S, von Tresckow J, Fink AM, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindström V, Staber P, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann C, Fischer K, Eichhorst B, Hallek M. Al-Sawaf O, et al. Among authors: lindstrom v. Blood. 2025 Nov 13;146(20):2406-2416. doi: 10.1182/blood.2025028899. Blood. 2025. PMID: 40864973 Free article.
The complexity of kidney disease and diagnosing it - cystatin C, selective glomerular hypofiltration syndromes and proteome regulation.
Malmgren L, Öberg C, den Bakker E, Leion F, Siódmiak J, Åkesson A, Lindström V, Herou E, Dardashti A, Xhakollari L, Grubb G, Strevens H, Abrahamson M, Helmersson-Karlqvist J, Magnusson M, Björk J, Nyman U, Ärnlöv J, Ridefelt P, Åkerfeldt T, Hansson M, Sjöström A, Mårtensson J, Itoh Y, Grubb D, Tenstad O, Hansson LO, Olafsson I, Campos AJ, Risch M, Risch L, Larsson A, Nordin G, Pottel H, Christensson A, Bjursten H, Bökenkamp A, Grubb A. Malmgren L, et al. Among authors: lindstrom v. J Intern Med. 2023 Mar;293(3):293-308. doi: 10.1111/joim.13589. Epub 2022 Dec 7. J Intern Med. 2023. PMID: 36385445 Free PMC article. Review.
Prehospital personnel's attitudes to pain management.
Castrèn M, Lindström V, Branzell JH, Niemi-Murola L. Castrèn M, et al. Among authors: lindstrom v. Scand J Pain. 2015 Jul 1;8(1):17-22. doi: 10.1016/j.sjpain.2015.02.003. Scand J Pain. 2015. PMID: 29911629 Free article.
Identification of cystatin C as a new marker of glomerular filtration rate, and of shrunken pore syndrome - a new kidney disorder defining selective glomerular hypofiltration syndromes - calls for expansion of the international KDIGO guidelines.
Åkesson A, Öberg C, Malmgren L, Nilsson C, Itoh Y, Blirup-Jensen S, Lindström V, Abrahamson M, Leion F, Olafsson I, Bjursten H, Grubb D, Herou E, Dardashti A, Sigurjonsson J, Xhakollari L, Laucyte-Cibulskiene A, Pottel H, Strevens H, Damm D, Förnvik Jonsson M, Siódmiak J, Ärnlöv J, Larsson A, Åkerfeldt T, Kultima K, Ridefelt P, Helmersson-Karlqvist J, Magnusson M, Hansson M, Sjöström A, Soveri I, Tenstad O, Mårtensson J, Elinder CG, Risch L, Risch M, Hansson LO, Price CP, Nyman U, Björk J, Delanaye P, Bökenkamp A, Christensson A, Grubb A. Åkesson A, et al. Among authors: lindstrom v. Scand J Clin Lab Invest. 2025;85(6):409-419. doi: 10.1080/00365513.2025.2546320. Epub 2025 Sep 1. Scand J Clin Lab Invest. 2025. PMID: 40888652 Free article. Review.
167 results